Status:
COMPLETED
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
Lead Sponsor:
Duke University
Conditions:
Hodgkin's Disease
Non Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Allogeneic transplantation is used to treat many malignant and non-malignant diseases. The investigators and others have shown that less toxic preparative regimens (reduced intensity or 'mini' transpl...
Detailed Description
Subjects will have toxicity monitored and reported per the Center for International Blood and Marrow Transplant Research (CIBMTR) program standard and as required by law for bone marrow transplant (BM...
Eligibility Criteria
Inclusion
- Recipient
- Subjects ≥ 18 years of age undergoing a reduced intensity allogeneic transplant
Exclusion
- Subjects \< 18 years of age
- Subjects not undergoing nonmyeloablative or ablative allogeneic transplant
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01904175
Start Date
August 1 2013
End Date
April 1 2016
Last Update
May 5 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Health System
Durham, North Carolina, United States, 27710